These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6365947)

  • 1. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women.
    Meldrum DR; Tsao Z; Monroe SE; Braunstein GD; Sladek J; Lu JK; Vale W; Rivier J; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1984 Apr; 58(4):755-7. PubMed ID: 6365947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
    Chang RJ; Laufer LR; Meldrum DR; DeFazio J; Lu JK; Vale WW; Rivier JE; Judd HL
    J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis.
    Meldrum DR; Chang RJ; Lu J; Vale W; Rivier J; Judd HL
    J Clin Endocrinol Metab; 1982 May; 54(5):1081-3. PubMed ID: 6801075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of gonadotropin-releasing hormone agonist action in the human male.
    Bhasin S; Swerdloff RS
    Endocr Rev; 1986 Feb; 7(1):106-14. PubMed ID: 3007079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of immunoreactive luteinizing hormone following gonadotropin-releasing hormone agonist therapy in women with endometriosis.
    Bischof P; Herrmann WL
    Gynecol Obstet Invest; 1988; 25(2):130-4. PubMed ID: 2967234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of hot flashes in premenopausal women treated with a long-acting GnRH agonist.
    DeFazio J; Meldrum DR; Laufer L; Vale W; Rivier J; Lu JK; Judd HL
    J Clin Endocrinol Metab; 1983 Mar; 56(3):445-8. PubMed ID: 6401756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin beta-subunit genes in normal and castrated rat pituitary.
    Lerrant Y; Kottler ML; Bergametti F; Moumni M; Blumberg-Tick J; Counis R
    Endocrinology; 1995 Jul; 136(7):2803-8. PubMed ID: 7789305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
    Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone and its agonist inhibit testicular luteinizing hormone receptor and steroidogenesis in immature and adult hypophysectomized rats.
    Bambino TH; Schreiber JR; Hsueh AJ
    Endocrinology; 1980 Oct; 107(4):908-17. PubMed ID: 6250797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.